Long-term preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice

Human Gene Therapy

Volumn 23, Issue 6, 2012, Pages 566-575

  Schinkel, Stefanie ^a   Bauer, Ralf ^a   Bekeredjian, Raffi ^a   Stucka, Rolf ^b   Rutschow, Désirée ^a   Lochmüller, Hanns ^c   Kleinschmidt, Jürgen A ^d   Katus, Hugo A ^a   Müller, Oliver J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DYSTROPHIN; MICRODYSTROPHIN; MYOSIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOSKELETON; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; GENE TRANSFER; HEART CATHETERIZATION; HEART FUNCTION; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MORTALITY; MOUSE; MUSCLE CONTRACTION; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DYSTROPHIN; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED MDX; MYOCARDIUM; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

ADENO-ASSOCIATED VIRUS; CYTOMEGALOVIRUS; MUS;

EID: 84864370685     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.017     Document Type: Article

References (42)

1. Alter, J., Lou, F., Rabinowitz, A., et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177. (Pubitemid 43214742)
2. Bauer, R., Straub, V., Blain, A., et al. (2009). Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur. J. Heart Fail. 11, 463-471.
3. Bostick, B., Yue, Y., Lai, Y., et al. (2008). Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum. Gene Ther. 19, 851-856.
4. Brooks, A.R., Harkins, R.N., Wang, P., et al. (2004). Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6, 395-404. (Pubitemid 40228056)
5. Cordier, L., Gao, G.P., Hack, A.A., et al. (2001). Muscle-specific promoters may be necessary for adeno-associated virusmediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther. 12, 205-215. (Pubitemid 32095458)
6. Crisp, A., Yin, H., Goyenvalle, A., et al. (2011). Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum. Mol. Genet. 20, 413-421.
7. Dressman, D., Araishi, K., Imamura, M., et al. (2002). Delivery of a-and b-sarcoglycan by recombinant adeno-associated virus: Efficient rescue of muscle, but differential toxicity. Hum. Gene Ther. 13, 1631-1646. (Pubitemid 35034683)
8. Dubielzig, R., King, J.A.,Weger, S., et al. (1999). Adeno-associated virus type 2 protein interactions: Formation of pre-encapsidation complexes. J. Virol. 73, 8989-8998. (Pubitemid 29487052)
9. Emery, A.E. (1991). Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul. Disord. 1, 19-29.
10. Ervasti, J.M., and Campbell, K.P. (1991). Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121-1131. (Pubitemid 121001402)
11. Foster, H., Sharp, P.S., Athanasopoulos, T., et al. (2008). Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther. 16, 1825-1832.
12. Fougerousse, F., Bartoli, M., Poupiot, J., et al. (2007). Phenotypic correction of a-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector. Mol. Ther. 15, 53-61. (Pubitemid 46043649)
13. Franz, W.M., Muller, M., Muller, O.J., et al. (2000). Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. Lancet 355, 1781-1785. (Pubitemid 30265083)
14. Gao, G., Vandenberghe, L.H., Alvira, M.R., et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388. (Pubitemid 38715936)
15. Hauswirth, W.W., Lewin, A.S., Zolotukhin, S., and Muzyczka, N. (2000). Production and purification of recombinant adenoassociated virus. Methods Enzymol. 316, 743-761. (Pubitemid 30235704)
16. Hor, K.N., Wansapura, J., Markham, L.W., et al. (2009). Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: A cardiac magnetic resonance tagging study. J. Am. Coll. Cardiol. 53, 1204-1210.
17. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53. (Pubitemid 43899488)
18. Jorgensen, L.H., Larochelle, N., Orlopp, K., et al. (2009). Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of Duchenne muscular dystrophy. Hum. Gene Ther. 20, 641-650.
19. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-ofconcept study. Lancet Neurol. 8, 918-928.
20. Koo, T., Malerba, A., Athanasopoulos, T., et al. (2011). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of a1-syntrophin and a-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther. 22, 1379-1388.
21. Lu, Q.L., Rabinowitz, A., Chen, Y.C., et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U.S.A. 102, 198-203. (Pubitemid 40094452)
22. Mendell, J.R., Campbell, K., Rodino-Klapac, L., et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429-1437.
23. Müller, O.J., Leuchs, B., Pleger, S.T., et al. (2006). Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res. 70, 70-78.
24. Muntoni, F., Cau, M., Ganau, A., et al. (1993). Brief report: Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N. Engl. J. Med. 329, 921-925. (Pubitemid 23275273)
25. Nigro, G., Comi, L.I., Politano, L., and Bain, R.J. (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 271-277. (Pubitemid 20061348)
26. Pacak, C.A., Mah, C.S., Thattaliyath, B.D., et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3-e9. (Pubitemid 44255502)
27. Quinlan, J.G., Hahn, H.S., Wong, B.L., et al. (2004). Evolution of the mdx mouse cardiomyopathy: Physiological and morphological findings. Neuromuscul. Disord. 14, 491-496. (Pubitemid 39141704)
28. Raake, P., Von Degenfeld, G., Hinkel, R., et al. (2004). Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: Comparison with surgical and percutaneous intramyocardial gene delivery. J. Am. Coll. Cardiol. 44, 1124-1129. (Pubitemid 39165150)
29. Sejerson, T., and Bushby, K.; TREAT-NMD EU Network of Excellence. (2009). Standards of care for Duchenne muscular dystrophy: Brief TREAT-NMD recommendations. Adv. Exp. Med. Biol. 652, 13-21.
30. Shin, J.H., Nitahara-Kasahara, Y., Hayashita-Kinoh, H., et al. (2011). Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther. 18, 910-919.
31. Spurney, C.F., Knoblach, S., Pistilli, E.E., et al. (2008). Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul. Disord. 18, 371-381.
32. Straub, V., and Campbell, K.P. (1997). Muscular dystrophies and the dystrophin-glycoprotein complex. Curr. Opin. Neurol. 10, 168-175. (Pubitemid 27196807)
33. Townsend, D., Blankinship, M.J., Allen, J.M., et al. (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092. (Pubitemid 46813611)
34. Townsend, D., Yasuda, S., Li, S., et al. (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol. Ther. 16, 832-835. (Pubitemid 351587091)
35. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl J. Med. 357, 2677-2686.
36. van Erp, C., Loch, D., Laws, N., et al. (2010). Timeline of cardiac dystrophy in 3-18-month-old MDX mice. Muscle Nerve 42, 504-513.
37. Veldwijk, M.R., Topaly, J., Laufs, S., et al. (2002). Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6, 272-278. (Pubitemid 36336136)
38. Vianello, A., Bevilacqua, M., Salvador, V., et al. (1994). Longterm nasal intermittent positive pressure ventilation in advanced Duchenne's muscular dystrophy. Chest 105, 445-448. (Pubitemid 24066715)
39. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 97, 13714-13719.
40. Welch, E.M., Barton, E.R., Zhuo, J., et al. (2007). PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87-91. (Pubitemid 46685839)
41. Willmann, R., Possekel, S., Dubach-Powell, J., et al. (2009). Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul. Disord. 19, 241-249.
42. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism inmice after systemic injection. Mol. Ther. 16, 1073-1080. (Pubitemid 351737072)